Modulators of protein tyrosine phosphatases (ptpases)

Disclosed are novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTPalpha, LAR and HePTP or the like, wher...

Full description

Saved in:
Bibliographic Details
Main Authors LUKE MILBURN JUDGE, YU GE, HENRIK SUNE ANDERSEN, THOMAS KRUSE HANSEN, WILIAM CHARLES RIPKA, JESPER LAU, NIELS PETER HUNDAHL MOLLER, DANIEL DALE HOLSWORTH, OLE HVILSTED OLSEN, ROY TERUYUKI UYEDA, FRANK URBAN AXE, BARRY ZVI SHAPIRA, TODD KEVIN JONES
Format Patent
LanguageEnglish
Published 17.04.2001
Edition7
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Disclosed are novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTPalpha, LAR and HePTP or the like, wherein n, m, X, Y, R1, R2, R3, R4, R5 and R6 are defined more fully in the description. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, and other diseases.
Bibliography:Application Number: AU20000069853